Open AccessUse of multikinase inhibitors/lenvatinib concomitant with locoregional therapies for the treatment of radioiodine‐refractory differentiated thyroid cancer
Author(s) -
BercianoGuerrero MiguelÁngel
Publication year - 2022
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.5108
Subject(s) - lenvatinib , medicine , concomitant , refractory (planetary science) , thyroid cancer , oncology , cancer research , cancer , biology , astrobiology
Abstract Locoregional recurrence of differentiated thyroid cancer (DTC) occurs in 20% of thyroid cancer patients. Currently, there are many strategies for management of locoregional recurrence of DTC that lead to local control of the disease. The introduction of lenvatinib into the therapeutic armamentarium provides a new option for the treatment of radioiodine‐refractory DTC (RR‐DTC). However, results for simultaneous treatment with lenvatinib and locoregional therapies are unknown in patients with RR‐DTC. This paper reviews the current status of this approach and gives recommendations on the management of lenvatinib during concomitant locoregional procedures.